Regulation And Legal
Biocon Receives FDA Form 483 with Five Observations
U.S. FDA completed a Pre-License Inspection at Biocon's Bengaluru biosimilars site from April 20-29, 2026.
The inspection covered 3 biologics manufacturing units, 5 quality labs, and 2 warehouses.
FDA
